Luye Pharma Group Ltd.
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
- Conditions
- Schizoaffective DisorderSchizo Affective DisorderSchizophrenia
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03751488
- Locations
- 🇺🇸
Collaborative Neuroscience Network LLC, Garden Grove, California, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
A Study of LY03005 vs Pristiq
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03733574
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03733561
- Locations
- 🇺🇸
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03589066
- Locations
- 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung CancerNon Small Cell Lung Cancer RecurrentNon Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 648
- Registration Number
- NCT03533127
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Chaoyang, Beijing, China
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT03450109
- Locations
- 🇺🇸
Pinnacle Research LLC, Anniston, Alabama, United States
🇺🇸South Florida Medical Research, Aventura, Florida, United States
🇺🇸Clinical Research Center of Flordia, Pompano Beach, Florida, United States
A Study to Evaluate the Denosumab in Healthy Adults
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03427853
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Xicheng District, China
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03357796
- Locations
- 🇺🇸
Clinilabs, Inc., Eatontown, New Jersey, United States
Pilot BA Study of New LY03005 vs Pristiq
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02988024
- Locations
- 🇺🇸
Clinilabs, Inc., Eatontown, New Jersey, United States
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT02728947
- Locations
- 🇺🇸
CNS Network, Long Beach, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States